Skip to main navigation

Home
News & Presentations
Governance
Financials
Stock Information
Resources

News Releases

News Releases

Year

Oct 04, 2021

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

Sep 30, 2021

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

Sep 28, 2021

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

Sep 27, 2021

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

Sep 09, 2021

Arcutis to Present at Upcoming Investor Conferences

Sep 02, 2021

Arcutis Announces Appointment of Keith Leonard to Board of Directors

Aug 25, 2021

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

Aug 23, 2021

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

Aug 05, 2021

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

Aug 02, 2021

Arcutis Announces Additions to its Investor Relations and Communications Team

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 37

Print Page

RSS Feeds

Email Alerts

Search

information@arcutis.com

linkedin

Who We Are
Our Focus
Pipeline
Clinical Trials
Investors
Contact
News / Press
Legal Disclaimer

© 2021 Arcutis Biotherapeutics